Cerebral to pay nearly $3.7M over controlled substance prescribing practices

WASHINGTON — The Federal Trade Commission (FTC) and HHS jointly issued a request for information on the practices of “opaque middlemen” in the pharmaceutical supply

Clear­side Bio­med­ical re­port­ed pos­i­tive re­sults from a Phase 2b tri­al of its ty­ro­sine ki­nase in­hibitor in pa­tients with wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, bol­ster­ing its prospects